Cell-penetrating peptides may cross the plasma membrane directly, enter through endocytosis, or use both routes. The apparent mechanism depends on the peptide, cargo, concentration, cell system, and assay.
A mechanism-first guide to the biotechnology evidence ladder, from biochemical assays and cultured cells to nonclinical models, human trials, regulatory review, and post-market monitoring.
Constitutive NF-κB activation is an experimental conclusion, not a synonym for one positive assay. This guide explains the evidence needed to demonstrate persistent baseline signaling and pathway dependence in cancer models.
A practical guide to CPP–protein architectures, linker selection, cargo-dependent behavior, and the evidence needed to demonstrate functional intracellular delivery.
Cell-penetrating peptides do not have one universal cargo-size limit. Productive delivery depends on the complete construct, its uptake route, intracellular release, localization, and retained activity.
A cell-penetrating peptide may enter cultured cells efficiently yet fail to deliver its cargo selectively to a target tissue in vivo. This guide explains the biological distinction and the evidence needed to evaluate selectivity.
A methods-focused guide to separating plasma-membrane binding, true CPP internalization, endosomal retention, and cytosolic delivery.
A chronological, evidence-led examination of CB5005, from its dual-function sequence and foundational patent to later glioma and lung-cancer delivery studies.
A mechanism-first explanation of how TNF-α activates canonical NF-κB through TNFR1, ubiquitin-organized signaling, TAK1, IKK, and IκBα degradation.
A mechanism-focused guide to the canonical NF-κB p50/RelA heterodimer, from subunit composition and DNA binding to localization and assay interpretation.